ReviewClinical utility of caspofungin eye drops in fungal keratitis
Introduction
Infections of the cornea are a major cause of blindness worldwide, especially in developing countries; fungal infections are a particularly noteworthy cause of morbidity [1], [2]. In certain parts of the world, more than one-half of corneal ulcers are due to fungal infections [3]. Fungal keratitis, also known as mycotic keratitis or keratomycosis, is characterised by a defect of the corneal epithelium with inflammation of the underlying stroma owing to fungal aetiology [4] and is particularly difficult to treat [5]. It responds poorly or not at all to antifungal treatment and may require surgical intervention [6]. Although the outcome for patients with early-stage fungal keratitis is reasonably good, for moderate-to-severe cases the chances of successful restoration of vision are ≤50% [7], [8], [9]. The limited range of antifungal eye drops available for treatment and the lack of favourable outcomes with existing antifungal eye drops [10] are major hurdles to successfully treating fungal keratitis; hence, alternatives are urgently needed. Topical application of newer antifungal agents that are currently available only for injection, such as the echinocandins (e.g. caspofungin), is worthy of consideration. In addition to increasing therapeutic options, this approach is likely to be more economically favourable than parenteral administration. While focusing on the efficacy, safety and practicality of using caspofungin eye drops in treating fungal keratitis, this review will also provide an overview of the incidence, epidemiology and current antifungal treatment options for this condition.
Section snippets
Incidence and epidemiology of fungal keratitis
The incidence of and causative pathogens associated with fungal keratitis vary by geographical region [11], more specifically by latitudinal variation, local climate, extent of urbanisation, occupational and/or economic factors [12], [13]. Fungal keratitis occurs more frequently in developing countries and in the tropics, including India [14], [15], [16], [17], Ghana [18], Nepal [19] and Burma [20], and accounts for ca. 50% of corneal infections in these regions. Other nations, including
Antifungal treatment
Use of appropriate topical antifungal agents remains the first-line therapeutic option [5]. It has been recommended that topical antifungal therapy should be initiated hourly around the clock for the first 24–48 h and then gradually tapered according to the clinical response [10] once laboratory confirmation of the causative fungal pathogen is available [44]. In most cases prolonged therapy of ≥6 weeks is required, with 12 weeks for filamentous and deep stromal infections [31]. The two key
Conclusions and future research direction
Topical treatment for fungal keratitis remains inadequate, and alternative antifungal eye drops are urgently needed. Caspofungin eye drops appear to be a potentially useful alternative for fungal keratitis. However, information related to the treatment outcome of using different concentrations of caspofungin eye drops as well as the optimal dosing frequency and duration of treatment remains scant. Indeed, there is a paucity of clinical experience in using caspofungin eye drops in treating
References (161)
- et al.
Microbial keratitis in Hong Kong: relationship to climate, environment and contact-lens disinfection
Trans R Soc Trop Med Hyg
(2001) - et al.
Spectrum of microbial keratitis in South Florida
Am J Ophthalmol
(1980) - et al.
Epidemiologic characteristics, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal
Am J Ophthalmol
(1991) - et al.
The changing spectrum of fungal keratitis in south Florida
Ophthalmology
(1994) - et al.
Spectrum of fungal keratitis in North China
Ophthalmology
(2006) - et al.
5-Fluorocytosine treatment of meningeal and pulmonary aspergillosis
Am J Med
(1973) - et al.
Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis
Am J Ophthalmol
(1986) Miconazole therapy for keratomycosis
Am J Ophthalmol
(1981)- et al.
The effects of intravenous miconazole on fungal keratitis
Am J Ophthalmol
(1984) Oral ketoconazole therapy for keratomycosis
Am J Ophthalmol
(1983)
Topical ketoconazole for fungal keratitis
Am J Ophthalmol
Penetration of topical fluconazole into human aqueous humor
Exp Eye Res
In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens
Am J Ophthalmol
Corneal blindness: a global perspective
Bull World Health Organ
Global data on visual impairment in the year 2002
Bull World Health Organ
Fungal keratitis
Curr Opin Ophthalmol
Infectious keratitis
Curr Opin Infect Dis
Medical interventions for fungal keratitis
Cochrane Database Syst Rev
Therapeutic keratoplasty for infectious keratitis: a review of the literature
CLAO J
Fungal keratitis at the University of Minnesota: 1971–1981
Trans Am Ophthalmol Soc
Keratomycosis in a New England referral center: spectrum of pathogenic organisms and predisposing factors
Advanced Fusarium keratitis progressing to endophthalmitis
Cornea
The challenge of fungal keratitis
Br J Ophthalmol
Geographic variations in microbial keratitis: an analysis of the peer-reviewed literature
Br J Ophthalmol
Microbial keratitis in South India: influence of risk factors, climate, and geographical variation
Ophthalmic Epidemiol
Epidemiological and microbiological diagnosis of suppurative keratitis in Gangetic West Bengal, Eastern India
Indian J Ophthalmol
Demographic pattern, predisposing factors and management of ulcerative keratitis: evaluation of one thousand unilateral cases at a tertiary care centre
Clin Experiment Ophthalmol
Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India
Br J Ophthalmol
Aetiology of suppurative corneal ulcers in Ghana and South India, and epidemiology of fungal keratitis
Br J Ophthalmol
Causes of suppurative keratitis in Ghana
Br J Ophthalmol
Laboratory diagnosis in ulcerative keratitis
Ophthalmic Res
Corneal ulceration in South East Asia. II. A strategy for the prevention of fungal keratitis at the village level in Burma
Br J Ophthalmol
Initial therapy for suppurative microbial keratitis in Iraq
Br J Ophthalmol
Suppurative corneal ulceration in Bangladesh. A study of 142 cases examining the microbiological diagnosis, clinical and epidemiological features of bacterial and fungal keratitis
Aust N Z J Ophthalmol
Epidemiological characteristics of microbiological results on patients with infectious corneal ulcers: a 13-year survey in Paraguay
Graefes Arch Clin Exp Ophthalmol
Predisposing factors and etiologic diagnosis of ulcerative keratitis
Cornea
Microbial keratitis in West Anatolia, Turkey: a retrospective review
Int Ophthalmol
Suppurative keratitis in London
Fungal keratitis in Melbourne
Clin Experiment Ophthalmol
Risk factors and causative organisms in microbial keratitis
Cornea
Ulcerative keratitis. Survey of 30 years’ laboratory experience
Arch Ophthalmol
Fungal infections of the cornea
Eye (Lond)
Mycotic keratitis in Paraguay
Mycoses
Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study
CLAO J
The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India
Cornea
Fungal keratitis in far North Queensland, Australia
Clin Experiment Ophthalmol
Fungal keratitis in France
Acta Ophthalmol
Fungal keratitis: changing pathogens and risk factors
Cornea
Fungal keratitis in London: microbiological and clinical evaluation
Cornea
Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania
Cornea
Cited by (27)
A dual-functional chitosan derivative platform for fungal keratitis
2022, Carbohydrate PolymersCitation Excerpt :Failure to rapidly and effectively cure fungal keratitis could gradually develop into corneal perforation or even endophthalmitis, which occurs in up to 50% of cases (Prajna et al., 2017; Relhan et al., 2017; Whitcher et al., 2001). However, current commercial antifungal agents (such as amphotericin B and natamycin) have low water solubility and instability and can also cause non-specific toxicity for the normal cells (Fukushima et al., 2013; Neoh et al., 2014; Sun et al., 2014; Wu et al., 2015). In addition, two major ocular intrinsic barriers (the tear film barrier and the corneal barrier) generally lead to ineffective ocular drug delivery and thus poor therapeutic effects against fungal keratitis.
Diseases of the Eye
2019, Large Animal Internal MedicineFungal keratitis caused by acremonium: A case report and literature review
2018, Journal Francais d'OphtalmologieFungal Keratitis: Diagnosis, Management, and Recent Advances
2024, Clinical OphthalmologyOvercoming the Stromal Barrier of the Cornea with a Peptide Conjugate Nano-Assembly to Combat Fungal Keratitis
2023, Advanced Healthcare Materials